TTP Investments Inc. Invests $249,000 in Hims & Hers Health, Inc. $HIMS

Key Points

• TTP Investments Inc. has taken a new position in Hims & Hers Health, acquiring 5,000 shares valued at approximately $249,000.
• Insider activity has seen significant sales, including insider Irene Becklund selling 8,410 shares for $424,705, indicating a 85.57% decrease in her position.
• Analyst ratings on Hims & Hers Health are mixed, with two ratings as "Buy," eight as "Hold," and three as "Sell," and a consensus target price of $38.92.

TTP Investments Inc. bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 5,000 shares of the company's stock, valued at approximately $249,000.

Other institutional investors have also recently made changes to their positions in the company. Webster Bank N. A. grew its position in shares of Hims & Hers Health by 229.1% during the second quarter. Webster Bank N. A. now owns 905 shares of the company's stock worth $45,000 after purchasing an additional 630 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in Hims & Hers Health during the 1st quarter valued at approximately $30,000. Parallel Advisors LLC grew its holdings in Hims & Hers Health by 175.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,155 shares of the company's stock valued at $58,000 after buying an additional 735 shares in the last quarter. UMB Bank n.a. grew its holdings in Hims & Hers Health by 247.5% during the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after buying an additional 933 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in Hims & Hers Health during the 1st quarter valued at approximately $41,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Trading Down 0.1%

Shares of HIMS stock traded down $0.05 on Monday, reaching $57.77. 18,693,929 shares of the company's stock were exchanged, compared to its average volume of 33,132,480. Hims & Hers Health, Inc. has a 52 week low of $16.05 and a 52 week high of $72.98. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The stock has a market capitalization of $13.06 billion, a PE ratio of 72.21, a P/E/G ratio of 3.91 and a beta of 2.14. The company's fifty day simple moving average is $50.71 and its 200 day simple moving average is $45.77.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.Hims & Hers Health's revenue was up 72.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on HIMS shares. Canaccord Genuity Group restated a "buy" rating and set a $68.00 price target on shares of Hims & Hers Health in a report on Friday, September 12th. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. UBS Group set a $30.00 price target on Hims & Hers Health in a report on Monday, June 23rd. Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Finally, Zacks Research cut Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Two equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Reduce" and an average price target of $38.92.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Irene Becklund sold 8,410 shares of Hims & Hers Health stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $424,705.00. Following the completion of the sale, the insider directly owned 1,418 shares of the company's stock, valued at $71,609. The trade was a 85.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Patrick Harrison Carroll sold 10,021 shares of Hims & Hers Health stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total value of $506,060.50. Following the sale, the insider directly owned 169,940 shares of the company's stock, valued at approximately $8,581,970. This trade represents a 5.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,511,978 shares of company stock worth $76,944,116 over the last quarter. Insiders own 13.71% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.